Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.

NCT04779957 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT04779957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04779957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.
Lead sponsor
University Hospital, Toulouse
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2021
Completion date
August 9, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft failure, kidney transplantation